Responsibility in Drug Advertising Act of 2025 | ChamberLight

IN COMMITTEE· 119TH CONGRESS

Senate BillS 483Drug safety, medical device, and laboratory regulationBroadcasting, cable, digital technologies

Responsibility in Drug Advertising Act of 2025

INTRO FEB 6· LAST ACTION FEB 6

READING

3MIN

COSPONSORS

READER REACTIONS0 TOTAL

NO VOTES YET · BE THE FIRST

Introduced only

LEGISLATIVE PROGRESS

STEP 2 / 8

Introduced

In Committee

Reported

Passed Senate

Passed House

Conference

To President

Became Law

WHAT THE BILL DOES

AI-written

This bill matters because it fundamentally changes how new prescription drugs are introduced to the American public. If it becomes law, it would significantly reduce the immediate marketing push for drugs fresh out of the approval process. This could mean that patients and doctors would have more time to understand the full safety profile and real-world effectiveness of a drug before advertising influences demand.

Without this bill, drug companies can typically begin extensive advertising campaigns shortly after a drug is approved, which some argue can lead to patients asking for specific drugs based on ads, sometimes before all potential risks are fully understood. By restricting advertising, this bill aims to prioritize comprehensive information from healthcare providers and allow for more post-market data collection before widespread promotion. If it doesn't become law, the current system of direct-to-consumer drug advertising would continue as is, with new drugs being advertised potentially very soon after their approval.

KEY PROVISIONS

4AI-extracted

PROVISION 01

Forbids direct-to-consumer advertising for any newly approved drug for the first three years after its approval, including on social media.

This provision aims to prevent rapid market saturation with ads for drugs whose long-term effects might not yet be fully known.

PROVISION 02

Allows the Secretary of Health and Human Services to waive the advertising ban during the third year if advertising the drug would genuinely benefit public health.

This provides flexibility for drugs deemed critical for public health to be advertised earlier under specific circumstances.

PROVISION 03

Grants the Secretary the authority to prohibit direct-to-consumer advertising for a drug, even after the initial three-year period, if it is found to have significant adverse health effects.

This creates an ongoing mechanism to pull drug ads for safety reasons based on real-world data collected after a drug is on the market.

PROVISION 04

Requires the Secretary to update regulations governing drug advertisements within one year of the bill's enactment to implement these new rules.

This ensures that the practical steps for enforcing the new advertising restrictions are put in place promptly.

SPONSORSHIP

1 + 2

COSPONSOR BREAKDOWNBIPARTISAN · 0%

DEM 2 REP 0 IND 0

ACTION TIMELINE

2 EVENTS

FEB 6

Introduced in Senate

INTROREFERRAL

FEB 6

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

INTROREFERRAL

BILL INFO

TypeSenate Bill

NumberS 483

Congress119th

StatusIn Committee

IntroducedFeb 6, 2025

Last actionFeb 6, 2025

READER REACTIONS

OVERALL SENTIMENT

No reactions yet. Be the first to weigh in.

Discussion

Loading comments...

Call my reps

IN COMMITTEE· 119TH CONGRESS · HEALTH, EDUCATION, LABOR, AND PENSIONS COMMITTEE · INTRODUCED FEB 6, 2025

Senate BillS 483Drug safety, medical device, and laboratory regulationBroadcasting, cable, digital technologies

Responsibility in Drug Advertising Act of 2025

INTRODUCED FEB 6, 2025· LAST ACTION FEB 6, 2025

PASSAGE CHANCES

—%

READING

3 min

COSPONSORS

COMPLEXITY

Moderate

Call my reps

LEGISLATIVE PROGRESS

STEP 2 OF 8

Introduced

In Committee

Reported

Passed Senate

Passed House

Conference

To President

Became Law

Introduced
In Committee
Reported
Passed Senate
Passed House
Conference
To President
Became Law

WHAT THE BILL DOES

AI-written

KEY PROVISIONS

AI-extracted

high

Forbids direct-to-consumer advertising for any newly approved drug for the first three years after its approval, including on social media.

This provision aims to prevent rapid market saturation with ads for drugs whose long-term effects might not yet be fully known.

med

Allows the Secretary of Health and Human Services to waive the advertising ban during the third year if advertising the drug would genuinely benefit public health.

This provides flexibility for drugs deemed critical for public health to be advertised earlier under specific circumstances.

high

Grants the Secretary the authority to prohibit direct-to-consumer advertising for a drug, even after the initial three-year period, if it is found to have significant adverse health effects.

This creates an ongoing mechanism to pull drug ads for safety reasons based on real-world data collected after a drug is on the market.

med

Requires the Secretary to update regulations governing drug advertisements within one year of the bill's enactment to implement these new rules.

This ensures that the practical steps for enforcing the new advertising restrictions are put in place promptly.

DEADLINES & DATES

AI-extracted

An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)

Not later than 1 year after the date of enactment of this section

The Secretary shall revise existing regulations governing drug advertisements to implement the new restrictions.

1 year before the date of enactment of this section

The new direct-to-consumer advertising restrictions apply to any drug approved on or after this date.

GLOSSARY

AI-written

Direct-to-consumer advertising: Advertising of prescription drugs directly to the public through media like television, radio, print, or the internet, rather than only to healthcare professionals.
Federal Food, Drug, and Cosmetic Act (FFDCA): The main federal law that governs the safety of food, drugs, cosmetics, and medical devices in the United States.
Secretary: Refers to the Secretary of Health and Human Services, the head of the U.S. Department of Health and Human Services, which oversees the Food and Drug Administration (FDA).
Drug approved under section 505(c): A new drug that has gone through the full federal approval process by the Food and Drug Administration, confirming its safety and effectiveness for its intended use.
Sponsor: The company or entity that develops a new drug and submits it to the Food and Drug Administration for approval.
Prohibited act: An action that is against the law, specifically outlined in the Federal Food, Drug, and Cosmetic Act, which can lead to legal penalties.

ACTION TIMELINE

2 EVENTS

FEB 6, 25

Introduced in Senate

INTROREFERRAL

FEB 6, 25

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

INTROREFERRAL

READER REACTIONS

0 COMMENTS

WHAT DO YOU THINK?

What do you think?

0 votes

Discussion

Loading comments...

MORE INFORMATION

Committee Referrals

Health, Education, Labor, and Pensions CommitteeReferred

Feb 6, 2025

senate

Search

Responsibility in Drug Advertising Act of 2025

LEGISLATIVE PROGRESS

WHAT THE BILL DOES

KEY PROVISIONS

SPONSORSHIP

ACTION TIMELINE

BILL INFO

READER REACTIONS

Discussion

Responsibility in Drug Advertising Act of 2025

LEGISLATIVE PROGRESS

WHAT THE BILL DOES

KEY PROVISIONS

DEADLINES & DATES

GLOSSARY

ACTION TIMELINE

SPONSORS

READER REACTIONS

What do you think?

Discussion

MORE INFORMATION

Committee Referrals

Related Legislation